Compliance with First-Line AntiRetroViral Treatment (ART) for HIV Infection in the Era of Dolutegravir in Kinshasa, Democratic Republic of the Congo

Bongenya, Berry Ikolango; Sombo, Marie-Thérèse Ayanne Safi; Bumoko, Guy Makila Mabe; Kabengele, Benoit Obel; Lusakibanza, Mariano Manzo; Mesia, Gauthier K.; Kamangu, Erick Ntambwe

doi:10.4236/wja.2023.131002

Cited by 3 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These values are markers of the progress of patient treatment. They are also markers of anemia [20], and other forms of deficiencies [21] [22] [23]. These disturbances are due to the progress of the infection, the appearance of opportunistic infections, the effectiveness of the treatment, and the general condition of the patient on ART [21] [22] [23].…”

Section: Discussionmentioning

confidence: 99%

Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Bongenya,

Kabengele,

Sombo

et al. 2023

AID

View full text Add to dashboard Cite

Introduction: The sixth month appointment (M6) is crucial because at the start of the ART course, it is an indicator of the prognosis of the evolution of care and decision-making on the continuity of treatment. Objective: The objective of this study is therefore to present the profile of People Living with HIV under treatment with Dolutegravir 6 months after starting ART in Kinshasa. Methods: The present study is a cross-sectional view at M6 of a prospective cohort to determine the profile of People Living with HIV (PLHIV) after 6 months of ARV Treatment (ART) in Kinshasa, DRC. During the M6 appointment, from April to August 2022, a sample of 5 ml of blood was taken for the various analyzes from all HIV patients included. The collection of sociodemographic data as well as biological and clinical data was carried out under the same conditions as at inclusion. The parameters recorded during M6 were: age, sex, and religion, level of study, marital status, profession, socio-economic level, height, weight, Body Mass Index (BMI), clinical profile, opportunistic infections as well as biochemical and molecular assessment. Results: In M6, 62 patients were registered including 38 women (61.3%), thus giving a sex ratio of 1.58 in favor of women. Fifty-seven (57) patients did not How to cite this paper: Bongenya, B.I.,

show abstract

Section: Discussionmentioning

confidence: 99%

Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Bongenya,

Kabengele,

Sombo

et al. 2023

AID

View full text Add to dashboard Cite

show abstract

Virological and Molecular Profile of People Living with the Human Immunodeficiency Virus Starting Dolutegravir Based Antiretroviral Treatment in Kinshasa, Democratic Republic of Congo

Bongenya¹,

Tshinguta²,

Sombo³

et al. 2023

WJA

View full text Add to dashboard Cite

Virological Profile of People Living with HIV after 12 Months of Treatment with Dolutegravir in Kinshasa

Bongenya,

Sombo,

Bumoko

et al. 2023

WJA

View full text Add to dashboard Cite

Context: The evaluation of plasma Viral Load constitutes an indicator of the progression of the infection, the effectiveness and the tolerance of the treatment. Objective: The objective of this study is to present the virological profile of Patients Living with HIV (PLHIV) after 12 months of AntiRetro Viral Treatment (ART) based on Dolutegravir (DTG) in Kinshasa. Method: The present study is a cross-sectional view of the virological profile of the twelfth month of a prospective cohort of PLHIV at M12 of DTG-based ART in Kinshasa. During the M12 appointment, a blood sample was taken for Molecular Biology analyses from all PLHIV included. Result: During the M12 appointment, 28 patients were registered, including 16 (57.1%) women. Nine (9) patients (45.0%) had an undetectable Viral Load (VL). The median VL value was 3.18 log 10 RNA copies/mL (1530 RNA copies/mL). The mutations K65R, T69P/N, K70R and M184V have been listed as mutations conferring resistance to Nucleotide Reverse Transcriptase Inhibitors. No mutations associated with Dolutegravir were observed at M12. Conclusion: After 12 months of AntiRetroViral Treatment based on Dolutegravir, half of the Patients on first-line ART are in a state of virological failure.

show abstract

Compliance with First-Line AntiRetroViral Treatment (ART) for HIV Infection in the Era of Dolutegravir in Kinshasa, Democratic Republic of the Congo

Cited by 3 publications

References 4 publications

Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Profile of People Living with HIV after 24 Weeks of Treatment with Dolutegravir in Kinshasa

Virological and Molecular Profile of People Living with the Human Immunodeficiency Virus Starting Dolutegravir Based Antiretroviral Treatment in Kinshasa, Democratic Republic of Congo

Virological Profile of People Living with HIV after 12 Months of Treatment with Dolutegravir in Kinshasa

Contact Info

Product

Resources

About